Floatz logo

Mylotarg

Myelodysplastic Syndrome

Vor Biopharmaantibody_drug_conjugatePhase 2/3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
73/ 100

Competitive context

314 Active assets in the Myelodysplastic Syndrome cohort.

Asset / SponsorPhaseRating
Fludarabine
Sawa Ito, MD
Phase 4BB
Anti-Thymoglobulin, Rabbit
Peking University First Hospital
Phase 2/3BB
Cytosin-Arabinosid
The First Affiliated Hospital of Soochow University
Phase 4BB
FILGRASTIM
City of Hope Medical Center
Phase 4BB
Daunorubicin
OHSU Knight Cancer Institute
Phase 3BB

View all 50 →

Same molecule, other indications

Mylotarg is also rated in:

Infusions, IntravenousDormant
BB
Indicative ·
66 / 100
View asset →
acute myeloid leukemiaDormant
B
Indicative ·
63 / 100
View asset →
acute promyelocytic leukemiaDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →